Welcome to our dedicated page for Rhythm Pharmaceu SEC filings (Ticker: RYTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through a biotech filing that runs 300 pages of clinical data is hard enough; add rare-disease terminology and Rhythm Pharmaceuticals’ disclosures become downright daunting. Whether you need the latest Rhythm Pharmaceuticals quarterly earnings report 10-Q filing or want to track Rhythm Pharmaceuticals insider trading Form 4 transactions before the next data read-out, the challenge is finding what matters fast.
Stock Titan solves that problem. Our AI reads every 10-K, 10-Q, 8-K and proxy statement the moment it posts to EDGAR and delivers plain-language highlights—think cash runway trends, pivotal-trial costs, and patent-expiry clocks—so you can focus on decisions, not deciphering jargon. Looking for Rhythm Pharmaceuticals annual report 10-K simplified? It’s already condensed. Need Rhythm Pharmaceuticals Form 4 insider transactions real-time? Alerts arrive in seconds.
- AI-powered summaries that answer “understanding Rhythm Pharmaceuticals SEC documents with AI” in minutes
- Real-time feeds for Rhythm Pharmaceuticals executive stock transactions Form 4
- Side-by-side comparison of sequential trials inside every 10-Q earnings report filing analysis
- Key excerpts from Rhythm Pharmaceuticals proxy statement executive compensation—RSUs, milestone bonuses and all
- Rhythm Pharmaceuticals 8-K material events explained in plain English, from FDA label updates to financing rounds
Investors use these insights to monitor insider sentiment ahead of top-line data, gauge cash burn vs. runway, and benchmark executive incentives against regulatory goals. No more scrolling line-by-line; our platform surfaces what biopharma specialists actually need—from patient enrollment numbers to royalty obligations—so your biotech diligence stays sharp and timely.
Rhythm Pharmaceuticals director Camille L. Bedrosian received new equity compensation grants on June 24, 2025, consisting of:
- Stock Options: 7,037 options to purchase common stock at an exercise price of $63.66 per share, expiring June 23, 2035
- Restricted Stock Units (RSUs): 4,712 RSUs, each convertible into one share of common stock
Both grants will fully vest on the earlier of June 24, 2026 or the day before the 2026 annual stockholder meeting, subject to continued service. The options provide the right to purchase shares at the fixed exercise price, while the RSUs represent a contingent right to receive shares with no purchase requirement. This appears to be part of the company's regular director compensation program.
Rhythm Pharmaceuticals (Nasdaq: RYTM) filed an 8-K disclosing the June 24 2025 Annual Meeting results and a governance change.
- Officer exculpation amendment: Stockholders approved a charter change (55.5 M FOR / 3.5 M AGAINST) extending Delaware-permitted liability protection to certain officers; became effective upon June 25 2025 filing.
- Director elections: Jennifer Good re-elected with 55.6 M votes; Edward T. Mathers retained his seat with 35.2 M votes.
- Auditor confirmation: Ernst & Young LLP ratified for FY-2025 with 60.6 M (99.7 %) FOR.
- Say-on-pay: Executive compensation passed (40.9 M FOR, 18.1 M AGAINST).
- Quorum: 60.7 M votes present, representing 92.7 % of eligible votes.
No operational or financial metrics were updated; the lone material item is the officer liability shield, which may dilute shareholder recourse.
Rhythm Pharmaceuticals director Jennifer L. Good received new equity compensation grants on June 24, 2025, consisting of:
- 7,037 stock options with an exercise price of $63.66 per share, expiring June 23, 2035
- 4,712 restricted stock units (RSUs), each convertible into one share of common stock
Both grants will fully vest on the earlier of June 24, 2026 or the day before the 2026 annual stockholder meeting, subject to continued service. The options and RSUs were granted at $0 cost to the director. This appears to be part of the company's regular annual director compensation program. The filing was submitted by Stephen Vander Stoep as attorney-in-fact for Jennifer Good.
Rhythm Pharmaceuticals (RYTM) director Edward T. Mathers received new equity compensation grants on June 24, 2025. The awards consist of:
- Stock Options: 7,037 options with an exercise price of $63.66, exercisable until June 23, 2035
- Restricted Stock Units (RSUs): 4,712 units, each convertible to one common share
Both grants will fully vest on the earlier of June 24, 2026 or the day before the 2026 annual stockholder meeting, subject to continued service. The options provide the right to purchase shares at the specified strike price, while the RSUs represent a contingent right to receive shares upon vesting with no purchase requirement. This compensation structure aligns the director's interests with long-term shareholder value.
Rhythm Pharmaceuticals (RYTM) – Form 4 insider filing
Director Christophe Jean reported two equity awards dated 24 Jun 2025:
- Stock option: 7,037 shares of common stock, exercise price $63.66, expiration 23 Jun 2035. The option vests in full on the earlier of 24 Jun 2026 or the day before the company’s 2026 annual shareholder meeting, subject to continued board service.
- Restricted stock units (RSUs): 4,712 units, each convertible into one common share. Vesting schedule mirrors the option grant; the RSUs have no expiration date.
Both grants are coded "A" (acquired) and were made directly to the reporting person. Following the transactions, Jean beneficially owns 7,037 stock options and 4,712 RSUs; no common shares were reported in Table I and no sales occurred.
The filing represents routine non-cash director compensation and does not disclose any open-market purchase or sale of Rhythm Pharmaceuticals stock.
Form 4 overview: Rhythm Pharmaceuticals (RYTM) disclosed that director Stuart A. Arbuckle received new equity awards on 24 June 2025.
The filing records the grant of 7,037 stock options with a $63.66 exercise price, expiring 23 June 2035, and 4,712 restricted stock units (RSUs). Both awards fully vest on the earlier of 24 June 2026 or the day immediately before the 2026 annual stockholder meeting, provided the director remains on the board. No non-derivative common-stock transactions were reported, and the director now beneficially owns the full amount of these derivative securities.
This appears to be routine annual board compensation that aligns the director’s incentives with shareholders and carries minimal dilution, offering little direct impact on Rhythm’s near-term financial outlook.
Form 4 snapshot: On 06/24/2025, Rhythm Pharmaceuticals (ticker RYTM) filed a Form 4 reporting new equity awards to director Lynn A. Tetrault.
- Stock options: 7,037 options with a $63.66 exercise price, expiring 06/23/2035. Vest in full on the earlier of 06/24/2026 or the day before the 2026 annual meeting, subject to continued board service.
- Restricted stock units (RSUs): 4,712 units; each RSU converts into one common share. Vesting schedule matches the option grant; no expiration date.
- Post-grant holdings: 7,037 derivative securities (options) and 4,712 RSUs are now reported as beneficially owned. No common shares were bought or sold, and no dispositions occurred.
The filing reflects routine director compensation designed to align incentives; it does not disclose any share sales, purchases with cash, or changes to non-derivative ownership.
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) – Form 4 insider filing dated 26 June 2025
Director David W. J. McGirr reported the receipt of two new equity grants on 24 June 2025:
- 7,037 non-qualified stock options with an exercise price of $63.66, expiring 23 June 2035. The options vest in full on the earlier of 24 June 2026 or the day before the company’s 2026 annual shareholder meeting, subject to continued board service.
- 4,712 restricted stock units (RSUs), each convertible into one share of common stock, subject to the same vesting schedule as the options. RSUs have no expiration date.
Both transactions were coded “A” (acquired) and were reported as direct holdings. No shares were sold or otherwise disposed of, and no Rule 10b5-1 trading plan was indicated.
Following the grants, McGirr’s directly held derivative interests consist of 7,037 options and 4,712 RSUs. The filing does not disclose his current ownership of fully vested common shares, and there were no cash proceeds to the insider or the company at grant.
Investment view: The activity reflects routine annual director compensation. While insider equity awards can strengthen alignment between directors and shareholders, the aggregate 11,749 potential shares represent an immaterial fraction of Rhythm’s outstanding share count and pose only minimal future dilution. The absence of open-market purchases means there is no immediate demand signal for the stock.
Form 4 Overview – Rhythm Pharmaceuticals, Inc. (RYTM)
On 23 June 2025, Rhythm Pharmaceuticals filed a Form 4 disclosing that director Edward T. Mathers acquired common shares through the conversion of vested restricted stock units (RSUs).
- Transaction date: 18 June 2025
- Transaction code: M (exercise/settlement of derivative security)
- Securities acquired: 4,000 shares of common stock, delivered against 4,000 fully-vested RSUs
- Exercise price: $0 (RSU settlement, no cash paid)
Following the settlement, Mathers’ beneficial ownership is reported as 7,000 shares held directly and 5,771 shares held indirectly through the Edward Timothy Mathers Revocable Trust. The filing notes that the reporting person disclaims beneficial ownership of any trust-held shares in which he has no pecuniary interest.
No open-market purchases or sales were executed; the filing solely reflects an equity award vesting. All RSUs reported in Table II have now been converted and zero derivative securities remain outstanding under this specific grant.
For investors, the key takeaway is that a board member’s direct equity stake increased, albeit through a scheduled award rather than discretionary buying. While this does not inject fresh capital into the company, it modestly aligns the director’s incentives with shareholders and removes an overhang of unvested awards.
Rhythm Pharmaceuticals (RYTM) – Form 4 insider activity
On 06/18/2025, director Christophe Jean converted 4,000 fully-vested restricted stock units (RSUs) into an equal number of common shares (transaction code M). The RSUs carried a $0.00 exercise price and represented a one-for-one right to common stock.
Following the conversion, Jean directly owns 7,000 Rhythm shares and no remaining RSUs, according to the filing. No sales were disclosed.
The filing documents a modest increase in board-level ownership without any market sale, offering a limited but positive alignment signal for shareholders.
FAQ
What is the current stock price of Rhythm Pharmaceu (RYTM)?
What is the market cap of Rhythm Pharmaceu (RYTM)?
What does Rhythm Pharmaceuticals specialize in?
What is the company’s lead product?
How does IMCIVREE work?
What kind of diseases does Rhythm Pharmaceuticals target?
What is the global regulatory status of Rhythm’s therapies?
Does the company have a diversified product pipeline?
How does Rhythm Pharmaceuticals maintain its expertise?
What differentiates Rhythm in the competitive biopharmaceutical landscape?
